Jul 05, 2023
UnitedHealthcare has added the following specialty medical drugs to its Review at Launch Medication List:
- Elfabrio® (pegunigalsidase alfa-ixwj) for the treatment of adults with Fabry disease
- Qalsody™ (tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene
Providers are strongly encouraged to seek a pre-determination on new-to-market medications that are on the Review at Launch list, in order to ensure coverage. Please be aware if a pre-determination is not requested, UnitedHealthcare may later deny the service or item as not medically appropriate or not covered.
Contact your Amwins Connect Regional Sales Manager for further information.
